key: cord-0730068-a9psx3d8 authors: Yan, Xiquan; Huang, Huxiang; Wang, Changfeng; Jin, Zhaoxia; Zhang, Zhongwei; He, Jiangming; Yin, Siqing; Fan, Maiying; Huang, Juanshu; Chen, Fang; Zeng, Yong; Han, Xiaotong; Zhu, Yimin title: Follow-up study of pulmonary function among COVID-19 survivors 1 year after recovery date: 2021-05-29 journal: J Infect DOI: 10.1016/j.jinf.2021.05.034 sha: f9888b97b9bbb1b26afda77fb75311871f31466b doc_id: 730068 cord_uid: a9psx3d8 nan Coronavirus disease 2019 (COVID-19) is a novel systemic disease that affects multiple organs, with the lungs being most affected. [1] [2] [3] Previous studies have demonstrated that carbon monoxide diffusing capacity (DLCO) is impaired in patients who had recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at the time of discharge. 4 However, long-term pulmonary function in survivors is poorly understood. Here, we assessed pulmonary function in survivors who had recovered from SARS-CoV-2 infection 1 year previously. In this cohort study conducted from March 16 to March 28, 2021, we followed up a total of 119 survivors with SARS-CoV-2 infection who had been hospitalized during January 24-March 18, 2020 in Huanggang, Hubei Province, China. Study inclusion criteria included a previous COVID-19 diagnosis (positive PCR result for SARS-CoV-2) and the willingness and ability to provide informed consent. Baseline demographics, smoking status, body mass index and comorbidities were extracted from the electronic medical record. The severity of the disease was defined according to the World Health Organization COVID-19 guidelines. Severe COVID-19 refers to fever or suspected respiratory infection, plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 ≤ 93% on room air. Lung function tests were performed by technicians in the lung function laboratory using the Master Screen Body (Jaeger, Germany). The procedure followed was in accordance with American Thoracic Society/European Respiratory Society guidelines. Commission. All participants provided their written or verbal consent to participate. A total of 119 survivors participated in this study (asymptomatic, n=9; non-severe, n=82; severe, n=28) ( Table 1 ). The median patient age was 52.97 (±12.17) years; 49 survivors (41%) were men and 70 (59%) were women. Twenty-four survivors (20%) had at least one chronic comorbidity, 10 (8%) with hypertension and 11 (9%) with diabetes; only 2 (2%) patients were reported as having chronic obstructive pulmonary disease. There were no statistically significant differences in age, sex, body mass index, and smoking status among the three groups. Anomalies were found for the percent predicted DLCO (n=47, 39%), DLCO/alveolar volume (n=10, 8%), percent predicted total lung capacity (TLC; n=50, 42%), percent predicted residual volume (n=50, 42%), percent predicted forced expiratory volume in 1 second (FEV1; n=11, 9%), maximal mid-expiratory flow (MMEF) 75/25 (n=41, 34%), percent predicted forced vital capacity (FVC; n=11, 9%), and FEV1/FVC (n=6, 5%). As shown in Table 1 , there was no statistically significant difference in damaged diffusing capacity among groups with different disease severity, with 11% in the asymptomatic group, 38% in the non-severe group, and 54% in the severe group, respectively (P=0.605). However, the gradual decline in lung diffusion capacity among survivors was consistent with varying degrees of severity. There was no significant difference in other measures (TLC, RV/TLC, FVC, FEV1, FEV1/FVC, and MMEF 75/25) among COVID-19 survivors with different disease severity. Previous studies have shown that survivors of COVID-19 may have lung damage. [4] [5] [6] [7] In follow-up studies lasting 3-6 months among rehabilitating COVID-19 severe/critical patients, DLCO damage was the most common abnormality, accounting for 56%-82% of cases, followed by TLC deficiencies. 6-8 They found significant differences in diffusing capacity damage among groups with different disease severity. Alessia et al. found that 10 of 13 patients with COVID-19 pneumonia were damaged at the time of discharge. 9 After 6 weeks, lung function was improved but a certain degree of restrictive changes remained. 9 In this cohort study, lung functional impairment are highly prevalent in survivors with COVID-19 1 year after discharge. Forty-seven (39%) survivors had impaired diffusing capacity during the 1-year follow-up, with no significant difference between the severe and non-severe groups. This may indicate that pulmonary function damage from COVID-19 can improve over time. DLCO abnormalities occurred in 39% of survivors, indicating damaged intra-alveolar diffusion pathways. Autopsy in patients who died from SARS-CoV-2 infection showed diffuse alveolar injury, accompanied by thrombosed small vessels with remarkable associated hemorrhage. 10 In summary, in this cohort study, we found that lung functional impairment are highly prevalent in survivors with COVID-19 1 year after discharge, and persistent lung function impairment was found in about 40% of survivors. Lung damage might be related to pulmonary fibrosis. Further long-term research is needed to understand the mechanisms underlying long-term SARS-CoV-2-related pulmonary function damage. Clinical Characteristics of Coronavirus Disease 2019 in China Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city Clinical Characteristics and Prognosis of 218 Patients With COVID-19: A Retrospective Study Based on Clinical Classification Abnormal pulmonary function in COVID-19 patients at time of hospital discharge Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up Pulmonary function in patients surviving to COVID-19 pneumonia Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans YZ, XH, YZ and XY generated the research question and analysis plan. XY, HH, CW, ZJ, ZZ, JH, SY, MF, JH, FC were involved in data collection and clinical appointments. XY, HH, CW, ZJ, ZZ, JH, and SY were involved in data analysis. All authors were involved in the final manuscript preparation. No conflicts of interests declared by an author. Epidemic Prevention and Control, and Program of Hunan Science and Technology Department (2020SK1011, 2020SK1010, 2020SK3011).